Ghia, Emanuela M. http://orcid.org/0000-0002-6060-6106
Rassenti, Laura Z.
Choi, Michael Y.
Quijada-Álamo, Miguel
Chu, Elvin
Widhopf, George F. II
Kipps, Thomas J. http://orcid.org/0000-0002-0064-4549
Funding for this research was provided by:
Leukemia and Lymphoma Society (SCOR (7005-14))
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA236361)
University of California San Diego Foundation Blood Cancer Research Fund
Article History
Received: 25 October 2021
Revised: 27 February 2022
Accepted: 9 March 2022
First Online: 13 April 2022
Competing interests
: EMG, LZR, MQA, GFW, and EC have no conflict of interest. Zilovertamab was developed by TJK and his laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock and research funding. MYC and TJK also have received research funding from Pharmacyclics and AbbVie.